HCW Biologics
HCWB
12 hedge funds and large institutions have $2.17M invested in HCW Biologics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
78% more capital invested
Capital invested by funds: $1.22M → $2.17M (+$950K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$190K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$17.1K |
| 3 |
BlackRock
New York
|
+$9.15K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.75K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$398 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.16K |
| 2 |
Morgan Stanley
New York
|
-$4.77K |
| 3 |
Two Sigma Investments
New York
|
-$3.58K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$22 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
HighTower Advisors
Chicago,
Illinois
| $770K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $406K | +$8.75K | +22 | +3% |
|
|
CAM
3
Cresset Asset Management
Chicago,
Illinois
| $286K | +$190K | +477 | +653% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $284K | – | – | – |
|
|
BCM
5
Bridgeway Capital Management
Houston,
Texas
| $179K | – | – | – |
|
|
6
BlackRock
New York
| $108K | +$9.15K | +23 | +13% |
|
|
7
Two Sigma Investments
New York
| $57.6K | -$3.58K | -9 | -8% |
|
8
State Street
Boston,
Massachusetts
| $46.5K | – | – | – |
|
|
9
Northern Trust
Chicago,
Illinois
| $22.1K | +$17.1K | +43 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $8.01K | -$7.16K | -18 | -55% |
|
|
FWM
11
Focused Wealth Management
Newburgh,
New York
| $2.17K | – | – | – |
|
12
Wells Fargo
San Francisco,
California
| $219 | – | – | – |
|
|
13
Morgan Stanley
New York
| – | -$4.77K | -14 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$22 | – | – |
|
|
15
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$398 | +1 | New |
|
HCWB Hedge Fund Activity: Q2 2023 in Review
12 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q2 2023, worth a combined $2.17M — up 78% from $1.22M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HCWB positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Cresset Asset Management, adding an estimated $190K. The largest seller was Tower Research Capital (TRC), cutting an estimated $7.16K.
- 12 institutional investors held HCW Biologics (HCWB) as of Q2 2023, up from 11 in Q1 2023.
- Funds reported $2.17M of HCW Biologics stock for Q2 2023, up 78% quarter-over-quarter.
- 2 funds opened new HCW Biologics positions in Q2 2023 and 1 closed out, a net change of +1 holder.
- The largest HCW Biologics buyer in Q2 2023 was Cresset Asset Management, an estimated $190K added.
- The largest HCW Biologics seller in Q2 2023 was Tower Research Capital (TRC), an estimated $7.16K sold.
Based on aggregated 13F filings for Q2 2023.